

VCN Biosciences presents its results on chemosensitizing capabilities of VCN-01 in the Seventh International Meeting On Replicating Oncolytic Virus Therapeutics, held in Quebec (Canada).

VCN Biosciences was invited to present its recent results on the chemosensitization capabilities to gemcitabine of its lead candidate VCN-01 in the framework of the 7th edition of the International Meeting On Replicating Oncolytic Virus Therapeutics, that was held during June 15th to 18th in Old Quebec City, Quebec (Canada). The talk was conducted by Dr. Miriam Bazan-Peregrino, who presented preclinical data demonstrating that the combination of VCN-01 with gemcitabine (standard of care for pancreatic cancer patients) significantly enhances the effectiveness of each treatment alone. This package of data further supports VCN Biosciences' proposed clinical program with VCN-01 in patients with pancreatic cancer.